[go: up one dir, main page]

DK1635820T3 - Asenapin til behandling af skizofreni hos en patient med overvægt eller tilböjelighed til overvægt - Google Patents

Asenapin til behandling af skizofreni hos en patient med overvægt eller tilböjelighed til overvægt

Info

Publication number
DK1635820T3
DK1635820T3 DK04766041T DK04766041T DK1635820T3 DK 1635820 T3 DK1635820 T3 DK 1635820T3 DK 04766041 T DK04766041 T DK 04766041T DK 04766041 T DK04766041 T DK 04766041T DK 1635820 T3 DK1635820 T3 DK 1635820T3
Authority
DK
Denmark
Prior art keywords
obesity
asenapine
schizophrenia
patient
treatment
Prior art date
Application number
DK04766041T
Other languages
Danish (da)
English (en)
Inventor
Jeroen A Tonnaer
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Application granted granted Critical
Publication of DK1635820T3 publication Critical patent/DK1635820T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK04766041T 2003-06-12 2004-06-09 Asenapin til behandling af skizofreni hos en patient med overvægt eller tilböjelighed til overvægt DK1635820T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101721 2003-06-12
PCT/EP2004/051069 WO2004110437A1 (fr) 2003-06-12 2004-06-09 Asenapine destinee au traitement de la schizophrenie chez un patient presentant une surcharge ponderale ou une predisposition a la surcharge ponderale

Publications (1)

Publication Number Publication Date
DK1635820T3 true DK1635820T3 (da) 2008-09-08

Family

ID=33547705

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04766041T DK1635820T3 (da) 2003-06-12 2004-06-09 Asenapin til behandling af skizofreni hos en patient med overvægt eller tilböjelighed til overvægt

Country Status (24)

Country Link
US (1) US20060128688A1 (fr)
EP (1) EP1635820B1 (fr)
JP (1) JP2006527238A (fr)
KR (1) KR20060020664A (fr)
CN (1) CN1816335A (fr)
AR (1) AR044675A1 (fr)
AT (1) ATE395914T1 (fr)
AU (1) AU2004246820B2 (fr)
BR (1) BRPI0411237A (fr)
CA (1) CA2528365A1 (fr)
CY (1) CY1110366T1 (fr)
DE (1) DE602004013966D1 (fr)
DK (1) DK1635820T3 (fr)
ES (1) ES2305829T3 (fr)
IL (1) IL172397A (fr)
NO (1) NO20055884L (fr)
NZ (1) NZ544018A (fr)
PL (1) PL1635820T3 (fr)
PT (1) PT1635820E (fr)
RU (1) RU2352336C2 (fr)
SI (1) SI1635820T1 (fr)
TW (1) TWI327915B (fr)
WO (1) WO2004110437A1 (fr)
ZA (1) ZA200509904B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061311A1 (es) * 2005-04-07 2007-02-09 Organon Nv Forma cristalina ortorrombica del maleato de asenapina en el tratamiento de esquizofrenia
US7741358B2 (en) 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
EP3558276B1 (fr) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Système thérapeutique transdermique contenant de l'asénapine et du polysiloxane ou du polyisobutylène
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
WO2019243452A1 (fr) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Système thérapeutique transdermique contenant de l'asénapine
WO2020106330A1 (fr) * 2018-07-18 2020-05-28 Pillsy, Inc. Dispositif intelligent d'administration et de surveillance de médicament, kit et procédé d'utilisation pour des composés de pilules
KR20220113767A (ko) 2019-12-11 2022-08-16 코어셉트 쎄라퓨틱스 인코포레이티드 미리코릴란트로 항정신병약-유도 체중 증가를 치료하는 방법
RU2756614C1 (ru) * 2021-04-07 2021-10-04 Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) Способ поддержки принятия врачебных решений выбора антипсихотической терапии у больных шизофренией с целью профилактики акатизии

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ282394A (en) * 1994-03-02 1997-12-19 Akzo Nobel Nv Dissolving tablets contain a dibenz[2,3:6,7] oxepino[4,5-c]pyrrole derivative for sublingual or buccal administration
US5496831A (en) * 1994-05-13 1996-03-05 The General Hospital Corporation Inhibition of insulin-induced adiposis
AU2002232470B2 (en) * 2001-01-02 2005-11-03 Pharmacia & Upjohn Company Llc New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents

Also Published As

Publication number Publication date
CA2528365A1 (fr) 2004-12-23
SI1635820T1 (sl) 2008-08-31
BRPI0411237A (pt) 2006-07-11
ZA200509904B (en) 2006-12-27
IL172397A (en) 2010-06-16
RU2352336C2 (ru) 2009-04-20
PL1635820T3 (pl) 2008-10-31
AU2004246820A1 (en) 2004-12-23
DE602004013966D1 (de) 2008-07-03
ES2305829T3 (es) 2008-11-01
PT1635820E (pt) 2008-06-17
AU2004246820B2 (en) 2009-10-01
EP1635820B1 (fr) 2008-05-21
JP2006527238A (ja) 2006-11-30
WO2004110437A1 (fr) 2004-12-23
CY1110366T1 (el) 2014-04-09
KR20060020664A (ko) 2006-03-06
EP1635820A1 (fr) 2006-03-22
HK1084894A1 (en) 2006-08-11
TW200501946A (en) 2005-01-16
IL172397A0 (en) 2006-04-10
NZ544018A (en) 2008-07-31
TWI327915B (en) 2010-08-01
NO20055884L (no) 2006-01-03
CN1816335A (zh) 2006-08-09
AR044675A1 (es) 2005-09-21
RU2006101061A (ru) 2006-07-27
US20060128688A1 (en) 2006-06-15
ATE395914T1 (de) 2008-06-15

Similar Documents

Publication Publication Date Title
DK1830843T3 (da) Indolidon-derivater til behandling eller forebyggelse af fibrotiske sygdomme
DK1750640T3 (da) Anordning til patientforflytning med skrånende øvre overflade
DE60312236D1 (de) Antihaftkatheter
DE502005007353D1 (de) Zervikale zwischenwirbelprothese
DE602005024846D1 (de) Blutdialysator
DE602005018989D1 (de) Chirurgische Klemme
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
DK2609947T3 (da) Plasterlignende infusionsapparat
IL182609A0 (en) Yeast-based therapeutic for chronic hepatitis c infection
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DK1577319T3 (da) Proteinoprensning med præfiltrering
DK1581297T3 (da) Kateter med enhedsbestanddel
DE602005002413D1 (de) Wegwerfhöschen
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DE602005018315D1 (de) Rollstuhl
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
DK1678085T3 (da) Fluidbehandlingsindretning
GB2411354B (en) Use of Scutellaria for the treatment of viral infections
DK1734959T3 (da) Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter
DK1635820T3 (da) Asenapin til behandling af skizofreni hos en patient med overvægt eller tilböjelighed til overvægt
DK1670482T4 (da) Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme
DK1750713T3 (da) Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner
DK1835907T3 (da) Lægemidler til behandling eller forebyggelse af fibrotiske sygdomme
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
EP1765392A4 (fr) Polypetpides induisant l'apoptose